These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15482203)

  • 1. Hepatitis C drug discovery: in vitro and in vivo systems and drugs in the pipeline.
    Huang M; Deshpande M
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):375-88. PubMed ID: 15482203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New possibilities on the horizon for the treatment of hepatitis C virus infection: direct-acting antiviral therapy].
    Pár A
    Orv Hetil; 2010 Dec; 151(50):2045-56. PubMed ID: 21126947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future directions in therapy for chronic hepatitis C.
    Jensen DM; Ascione A
    Antivir Ther; 2008; 13 Suppl 1():31-6. PubMed ID: 18432161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promising candidates for the treatment of chronic hepatitis C.
    Walker MP; Yao N; Hong Z
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1269-80. PubMed ID: 12882616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New HCV therapies on the horizon.
    Vermehren J; Sarrazin C
    Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The era of direct-acting antivirals has begun: the beginning of the end for HCV?
    Vachon ML; Dieterich DT
    Semin Liver Dis; 2011 Nov; 31(4):399-409. PubMed ID: 22189979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meet the Classes of Directly Acting Antiviral Agents: Strengths and Weaknesses.
    Chacko KR; Gaglio PJ
    Clin Liver Dis; 2015 Nov; 19(4):605-17, v. PubMed ID: 26466650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
    Suzuki T
    Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
    Thomson JA; Perni RB
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel methods of hepatitis C treatment and prevention].
    Chmielewska AM; Rychłowska M; Król E; Solarz K; Bieńkowska-Szewczyk K
    Postepy Hig Med Dosw (Online); 2015 Aug; 69():946-63. PubMed ID: 26400881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational drugs for hepatitis C.
    Flisiak R; Parfieniuk A
    Expert Opin Investig Drugs; 2010 Jan; 19(1):63-75. PubMed ID: 20001555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of HCV protease inhibitors.
    Chen KX; Njoroge FG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
    Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hepatitis C virus: therapeutic targets and new drugs].
    Nikolaeva LI; Sapronov GV
    Vopr Virusol; 2012; 57(5):10-5. PubMed ID: 23248853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
    Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibitors of hepatitis C virus replication.
    Neyts J
    Antiviral Res; 2006 Sep; 71(2-3):363-71. PubMed ID: 16843538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches to the development of novel inhibitors of hepatitis C virus replication.
    Clarke BE
    J Viral Hepat; 1995; 2(1):1-8. PubMed ID: 7493290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral Research--16th International Congress: HBV and HCV. 27 April-1 May 2003, Savannah, GA, USA.
    Smee D
    IDrugs; 2003 Jun; 6(6):518-21. PubMed ID: 12861975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.